All the Active Ingredient Drugs
Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg. FC Tabs 60 X 5 mg
Rheumatoid arthritis:
5 mg twice/d, which should not be exceeded. No dose adjust. req. when used in comb. with methotrexate (MTX).
Psoriatic arthritis: 5 mg twice/d, which should not be exceeded.
No dose adjust. req. when used in comb. with MTX.
Ankylosing spondylitis: 5 mg twice/ d.
Ulcer. colitis –Induct. tmt.: 10 mg twice/d for 8 weeks.
For pts. who do not achieve adeq. therap. benefit by week 8, induct. dose can be extend. for an addit. 8 wks. (16 wks. total), followed by 5 mg twice/d for maint. Should be discont. in pts. who show no evid. of therap. benef. by wk. 16.
Ulcer. colitis –Mainten. tmt: 5 mg twice/d.
Juvenile idiopathic arthritis (JIA) dosing as per pt. weight:
betw 10 and 20 kg: 3. 2 mg X 2 dly
betw 20-40 kg: 4 mg X 2 dly
more than 40 kg: 5 mg X 2 dly. See full prescript. details
Rheumatoid arthritis: in combin. with methotrexate (MTX) for mod. to sev. active rheumatoid arthritis (RA) in adults who have respon. inadeq. to, or who are intol. to one or more dis.-modifying antirheumatic drugs (DMARDs). Can be given as monother. in case of intoler. to MTX or when MTX is inappropriate.Psoriatic arthritis: in combin. with MTX for active psoriatic arthritis (PsA) in adults who have had an inadeq. resp. or who have been intol. to a prior DMARD ther. Ulcerative colitis: for adults with moder. to sev. active ulcerative colitis (UC) who have had an inadeq. resp., lost resp, or were intol. to either convent. ther. or a bio. agent. Ankylosing spondylitis: for adults with active ankylosing spondylitis (AS) who have resp. inadeq. to convent. ther. Juvenile idiopathic arthritis (JIA): for active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in 2 years of age and older, who have resp. inadeq. to previous DMARDs. Can be given in combin. with MTX or as monother. in case of intoler. to MTX or where contin. tmt. with MTX is inapprop.
C/I: Hypersens. Active tuberc. (TB), serious infect. such as sepsis, or opportun. infect. • Severe hepatic impairm. • Pregn. and lactat.
Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg, 10 mg, XR 11 mg. FC Tabs: 28,60,180:, XR 14,30
Rheumatoid arthritis:
5 mg twice/d, or one XR tab. (11 mg)/d which should not be exceeded. No dose adjust. req. when used in comb. with methotrexate (MTX).
For info. on switching between tofacitinib tab. and tofacitinib XR tab. see prescr. details.
Psoriatic arthritis: 5 mg twice/d, which should not be exceeded.
No dose adjust. req. when used in comb. with MTX.
Ankylosing spondylitis:
5 mg twice/ d.
Ulcer. colitis –Induct. tmt.:
10 mg twice/d for 8 weeks.
For pts. who do not achieve adeq. therap. benefit by week 8, induct. dose can be extend. for an addit. 8 wks. (16 wks. total), followed by 5 mg twice/d for maint. Should be discont. in ptts. who show no evid. of therap. benef. by wk. 16.
Ulcer. colitis –Mainten. tmt:
5 mg twice/d.
Juvenile idiopathic arthritis (JIA) dosing as per ptt. weight:
betw 10 and 20 kg: 3. 2 mg X 2 dly
betw 20-40 kg: 4 mg X 2 dly
more than 40 kg: 5 g X 2 dly. See prescript. details
Rheumatoid arthritis (RA)
in comb. with MTX. for mod. to sev. active RA in adlt. pts. who have respond. inadeq. to, or who are intol. to one or more dis.-modif. antirheum. drugs (DMARDs). Can be given as monother. in case of intol. to MTX or when tmt. with MTX is inappropr.
Psoriatic arthritis (PsA)
in comb. with MTX for act. PsA in adlt. pts. who had an inadeq. respon. or had been intol. to a prior dis.-modif. antirheum. drug (DMARD) ther.
Ankylosing spondylitis (AS)
for adlt. pts. with act. AS who have respond. inadeq. to convent. ther.
Ulcerative colitis (UC)
for adlt. pts. with moder. to seve. act. UC who had an inadeq. respon., lost respon., or were intol. to either convent. ther. or a biologic agent.
Juvenile idiopathic arthritis (JIA)
tmt. of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have resp. inadeq. to prev. ther. with disease mod. antirheum. drugs (DMARDs).
Tofacitinib can be given in combin. with methotrexate (MTX) or as monother. in case of intol. to MTX or where continued tmt. with MTX is inappropr.
C/I: Hypersens • Active tuberc. (TB), serious infect. such as sepsis, or opportun. infect. • Severe hepatic impairm. • Pregn. and lactat.
Janus Kinase Inhibitor (JAKs). Tofacitinib 1 mg/ml. Oral sol. 240 ml
For 10-20 kg BW: 3.2 mg twice/d. For 20-40kg: 4 mg twice/d. Above 40 kg, 5 mg twice/d.
tmt of active polyarticular juvenile idiopathic arthritis (rheumatoid factor pos. [RF+] or neg. [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in pts 2 years of age and older, who have responded inadeq. to previous ther. with disease modifying antirheumatic drugs (DMARDs). This drug can be given in combin. with methotrexate (MTX) or as monother. in case of intoler. to MTX or where continued tmt. with MTX is inappropriate.
C/I: Hypersens., active TB, sev. hepatic impairm., pregn. and lact.
